Pangen Biotech Inc
222110
Company Profile
Business description
Pangen Biotech Inc is a biotechnology company. The company is engaged in the production and sales of biosimilar EPO drugs, contract manufacturing (CMO), and development technology transfer service (CDO) business for biopharmaceuticals, including non-clinical and clinical samples, and biopharmaceutical development business.
Contact
306 Sinwon-ro, Yeongtong-gu
4th floor, Yeongtong Innoplex 2nd building, Woncheon-dong
Gyeonggi-do
Suwon-si
KORT: +82 317339165
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
75
Stocks News & Analysis
stocks
Will undervalued ASX share show progress in results?
Investors will get to see if the new strategy and capital management framework are working.
stocks
10 best US dividend aristocrats to buy now for 2026
These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,250.60 | 50.70 | -0.55% |
| CAC 40 | 8,066.68 | 86.14 | -1.06% |
| DAX 40 | 24,822.79 | 71.65 | -0.29% |
| Dow JONES (US) | 49,001.67 | 1.74 | -0.00% |
| FTSE 100 | 10,154.43 | 53.37 | -0.52% |
| HKSE | 27,826.91 | 699.96 | 2.58% |
| NASDAQ | 23,844.25 | 27.15 | 0.11% |
| Nikkei 225 | 53,358.71 | 25.17 | 0.05% |
| NZX 50 Index | 13,412.87 | 98.01 | -0.73% |
| S&P 500 | 6,974.87 | 3.73 | -0.05% |
| S&P/ASX 200 | 8,933.90 | 40.40 | -0.45% |
| SSE Composite Index | 4,151.24 | 11.33 | 0.27% |